Chemotherapy sensitivity and resistance testing: To be "standard" or to be individualized, that is the question

Gastric Cancer

Volumn 9, Issue 2, 2006, Pages 82-87

  Kubota, Tetsuro ^a   Weisenthal, Larry ^b  

^a KEIO UNIVERSITY HOSPITAL   (Japan)

^b Weisenthal Cancer Group   (United States)

Author keywords

Chemosensitivity testing; Clinical trial; Gastric cancer; Histoculture drug response assay; MTT assay

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; PACLITAXEL;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL ACTIVITY; CELL CULTURE; CHEMOSENSITIVITY; CLONOGENIC ASSAY; DRUG ACTIVITY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; JAPAN; LABORATORY DIAGNOSIS; LYMPH NODE DISSECTION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANK SUM TEST; REVIEW; STATISTICAL SIGNIFICANCE; STOMACH CANCER; TREATMENT OUTCOME;

EID: 33745086616     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-006-0366-7     Document Type: Review

References (45)

1. DL Schipper DJ Wagener 1996 Chemotherapy of gastric cancer Anticancer Drugs 7 137 49
2. JS Macdonald JJ Gohmann 1988 Chemotherapy of advanced gastric cancer: present status, future prospects Semin Oncol 15 3 Suppl 4 42 9
3. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1∈M tegafur-0.4∈M gimestat-1∈M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 20
4. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 7
5. W Koizumi S Tanabe K Saigenji A Ohtsu N Boku F Nagashima 2003 Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 12
6. T Kondo T Kubota T Tanimura H Yamaue S Akiyama Y Maehara 2000 Cumulative results of chemosensitivity tests for antitumor agents in Japan Anticancer Res 20 2389 92
7. http://www.mhlw.go.jp/topics/0106/tp0601-1a.html
8. J Hermans JJ Bonenkamp MC Boon AMG Bunt S Ohyama M Sasako 1993 Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials J Clin Oncol 11 1441 7
9. JP Pignon M Ducreux P Rougier 1994 Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal J Clin Oncol 12 877 8
10. T Nakajima K Ohta S Ohyama N Hamajima 1999 Meta-analysis of adjuvant chemotherapy trials for gastric cancer at the Cancer Institute Hospital T Nakajima T Yamaguchi Multimodality therapy for gastric cancer Springer-Verlag Heidelberg Berlin New York Tokyo 27 31
11. CC Earle JA Maroun 1999 Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials Eur J Cancer 35 1059 64
12. E Mari I Floriani A Tinazzi A Buda M Belfiglio M Valentini 2000 Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) Ann Oncol 11 837 43
13. KG Janunger L Hafstroem P Nygren B Glimelius SBU-group. Swedish Council of Technology Assessment in Health Care 2001 A systematic overview of chemotherapy effects in gastric cancer Acta Oncol 40 309 26
14. I Panzini L Gianni PP Fattori D Tassinari M Imola P Fabbri 2002 Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses Tumori 88 21 7
15. Japanese Gastric Cancer Association 2001 Guideline of gastric cancer therapy 1st ed. Kanehara Tokyo
16. Japanese Gastric Cancer Association 2004 Guideline of gastric cancer therapy 2nd ed. Kanehara Tokyo
17. JS Macdonald SR Smalley J Benedetti SA Hundahl NC Estes GN Stemmermann 2001 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725 30
18. st ASCO, Abstract no. 4021; 2005. p. 313s
19. st ASCO Abstract no. 4001; 2005. p. 308s
20. Y Saikawa T Kubota T Furukawa A Suto M Watanabe K Kumai 1994 Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer Jpn J Cancer Res 85 762 5
21. T Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 55 63
22. Y Shimoyama T Kubota M Watanabe K Ishibiki O Abe 1989 Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to clonogenic assay J Surg Oncol 41 12 8
23. A Suto T Kubota Y Shimoyama K Ishibiki O Abe 1989 MTT assay with reference to the clinical effect of chemotherapy J Surg Oncol 42 28 32
24. T Furukawa T Kubota A Suto T Takahara H Yamaguchi T Takeuchi 1991 Clinical usefulness of chemosensitivity testing using the MTT assay J Surg Oncol 48 188 93
25. T Furukawa T Kubota M Watanabe T Takahara H Yamaguchi T Takeuchi 1992 High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point Int J Cancer 51 489 98
26. T Furukawa T Kubota M Watanabe S Kase T Takahara H Yamaguchi 1992 Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and MTT endpoint Anticancer Res 12 1377 82
27. T Furukawa T Kubota RM Hoffman 1995 Clinical applications of the histoculture drug response assay Clin Cancer Res 1 305 11
28. T Kubota N Sasano O Abe I Nakao E Kawamura T Saito 1995 Potential of the histoculture drug response assay to contribute to cancer patient survival Clin Cancer Res 1 1537 43
29. HJ Lenz CG Leichman KD Danenberg PV Danenberg S Groshen H Cohen 1996 Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor of primary tumor response and overall survival J Clin Oncol 14 176 82
30. JJ Grau J Domingo-Domenrech V Morente M Pera JC Garcia-Valdecasas J Fuster 2004 Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur Oncology 66 226 33
31. Y Ishikawa T Kubota Y Otani M Watanabe T Teramoto K Kumai 2000 Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil Jpn J Cancer Res 91 105 12
32. F Toriumi T Kubota Y Saikawa M Yoshida Y Otani M Watanabe 2004 Thymidylate synthetase genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric cancer Anticancer Res 24 2455 63
33. M Terashima H Fujiwara A Takagane K Abe T Irinoda T Nakaya 2003 Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer Gastric Cancer 6 Suppl 1 71 81
34. R Metzger CG Leichman KD Danenberg PV Danenberg HJ Lenz K Hayashi 1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J Clin Oncol 16 309 16
35. K Suganuma T Kubota Y Saikawa S Abe Y Otani T Furukawa 2003 Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray Cancer Sci 94 355 9
36. K Fujita T Kubota SW Matsusaki Y Otani M Watanabe T Teramoto 1998 Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer Anticancer Res 18 1973 8
37. S Abe T Kubota SW Matsuzaki Y Otani M Watanabe T Teramoto 1999 Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous gastric cancer Anticancer Res 19 4581 86
38. T Kubota T Egawa Y Otani T Furukawa Y Saikawa M Yoshida 2003 Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination Anticancer Res 23 583 8
39. DJ Samson J Seidenfeld K Ziegler N Aronson 2004 Chemotherapy sensitivity and resistance assays: a systematic review J Clin Oncol 22 3618 30
40. D Schrag HS Garewal HJ Burstein DJ Samson DD Von Hoff MR Somerfield 2004 American Society of Clinical Oncology Technology Assessment. Chemotherapy sensitivity and resistance assays J Clin Oncol 22 3631 8
41. Weisenthal LM, Nygren P. Current status of cell culture drug resistance testing (CCDRT). 2002. http://weisenthal.org/oncol_t.htm
42. S Paik S Shak G Tang C Kim J Baker M Cronin 2004 A multigene assay to predict recurrence to tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817 26
43. F Cappuzzo M Varella-Garcia H Shigematsu I Domenichini S Bartolini GL Ceresoli 2005 Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients J Clin Oncol 23 5007 18
44. Kubota T. Chemosensitivity test for adjuvant cancer chemotherapy of gastric cancer (JACCRO GC-04). Igaku no Ayumi (J Clin Exp Med) 2006;217
45. Nomura E, Tanigawa N. JCOG clinical trial for evaluation of the utility of in vitro chemosensitivity test for cancer. Igaku no Ayumi (J Clin Exp Med) 2006;217